Endotypes of Asian chronic rhinosinusitis with nasal polyps: A narrative review

IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Precision and Future Medicine Pub Date : 2022-09-07 DOI:10.23838/pfm.2022.00072
Gwanghui Ryu, H. Kim, Y. Jung, S. Hong
{"title":"Endotypes of Asian chronic rhinosinusitis with nasal polyps: A narrative review","authors":"Gwanghui Ryu, H. Kim, Y. Jung, S. Hong","doi":"10.23838/pfm.2022.00072","DOIUrl":null,"url":null,"abstract":"Chronic rhinosinusitis (CRS) is classified as CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRSwNP is a distinct phenotype with heterogeneous endotypes and complex pathophysiological mechanisms. Inflammation of the sinonasal mucosa that forms NPs causes symptoms such as nasal obstruction, rhinorrhea, and smell loss, and lowers patients’ quality of life. In recent years, researchers have attempted to elucidate the inflammatory endotypes of CRSwNP, and the inflammatory pattern of Asian CRSwNP was found to be different from that of Western CRSwNP. The main en-dotype of CRSwNP is type 2 inflammation, in which interleukin (IL)-4, IL-5, and IL-13 are key cytokines. In contrast, type 1 inflammation (interferon-γ) and type 3 inflammation (IL-17 or IL-22) play essential roles in Asian CRSwNP. Biological agents, which have recently been highlighted for the treatment of CRSwNP, are very effective in suppressing the type 2 inflammatory response and recovering smell loss. However, little information is available on the efficacy of these biologics in Asian patients with CRSwNP. Herein, we reviewed the endotypes of Asian CRSwNP and compared them to those of Western CRSwNP. We identified changes in the inflammatory patterns and summarized the therapeutic options for Asian CRSwNP.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision and Future Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23838/pfm.2022.00072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic rhinosinusitis (CRS) is classified as CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRSwNP is a distinct phenotype with heterogeneous endotypes and complex pathophysiological mechanisms. Inflammation of the sinonasal mucosa that forms NPs causes symptoms such as nasal obstruction, rhinorrhea, and smell loss, and lowers patients’ quality of life. In recent years, researchers have attempted to elucidate the inflammatory endotypes of CRSwNP, and the inflammatory pattern of Asian CRSwNP was found to be different from that of Western CRSwNP. The main en-dotype of CRSwNP is type 2 inflammation, in which interleukin (IL)-4, IL-5, and IL-13 are key cytokines. In contrast, type 1 inflammation (interferon-γ) and type 3 inflammation (IL-17 or IL-22) play essential roles in Asian CRSwNP. Biological agents, which have recently been highlighted for the treatment of CRSwNP, are very effective in suppressing the type 2 inflammatory response and recovering smell loss. However, little information is available on the efficacy of these biologics in Asian patients with CRSwNP. Herein, we reviewed the endotypes of Asian CRSwNP and compared them to those of Western CRSwNP. We identified changes in the inflammatory patterns and summarized the therapeutic options for Asian CRSwNP.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
亚洲慢性鼻窦炎伴鼻息肉的内分型:综述
慢性鼻窦炎(CRS)分为伴有鼻息肉的CRS(CRSwNP)和无鼻息肉的慢性鼻窦炎(CRSsNP)。CRSwNP是一种独特的表型,具有异质的内型和复杂的病理生理机制。形成NP的鼻腔粘膜炎症会导致鼻阻塞、鼻漏和嗅觉丧失等症状,并降低患者的生活质量。近年来,研究人员试图阐明CRSwNP的炎症内型,发现亚洲CRSwNP与西方CRSwNP不同的炎症模式。CRSwNP的主要基因型是2型炎症,其中白细胞介素(IL)-4、IL-5和IL-13是关键的细胞因子。相反,1型炎症(干扰素-γ)和3型炎症(IL-17或IL-22)在亚洲CRSwNP中起着重要作用。最近被强调用于治疗CRSwNP的生物制剂在抑制2型炎症反应和恢复嗅觉丧失方面非常有效。然而,关于这些生物制剂对亚洲CRSwNP患者的疗效信息很少。在此,我们回顾了亚洲CRSwNP的内型,并将其与西方CRSwNP进行了比较。我们确定了炎症模式的变化,并总结了亚洲CRSwNP的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Precision and Future Medicine
Precision and Future Medicine MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
10 weeks
期刊最新文献
Survival rate and death risk for associated pulmonary arterial hypertension: A retrospective population-based study Understanding hikikomori syndrome in clinical settings: a case series Development of colistin resistance via heteroresistance modeling in Klebsiella pneumoniae: A diagnostic study Paraneoplastic neurological syndrome associated with onconeural autoantibodies: report of two cases Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1